Literature DB >> 18625433

Hepatitis C virus infection and hepatocellular carcinoma.

Wojciech Blonski1, K Rajender Reddy.   

Abstract

Primary liver cancer is the sixth most common cancer in the world and the third most common cause of death attributable to cancer. Most primary liver cancers are hepatocellular carcinoma (HCC), accounting for 85% to 90% of cases. There is a trend of growing incidence of HCC in the United States. One of the most important risk factors for developing HCC is chronic hepatitis C virus (HCV) infection. Although several studies suggested the preventive effect of interferon from developing HCC in HCV-infected individuals, these findings need to be validated in large prospective and randomized trials.

Entities:  

Mesh:

Year:  2008        PMID: 18625433     DOI: 10.1016/j.cld.2008.03.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  15 in total

1.  Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics.

Authors:  Sarah Billington; Adrian S Ray; Laurent Salphati; Guangqing Xiao; Xiaoyan Chu; W Griffith Humphreys; Mingxiang Liao; Caroline A Lee; Anita Mathias; Cornelis E C A Hop; Christopher Rowbottom; Raymond Evers; Yurong Lai; Edward J Kelly; Bhagwat Prasad; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-11-14       Impact factor: 3.922

2.  Prevalence and risk factors of asymptomatic hepatitis C virus infection in bangladesh.

Authors:  Fazal Karim; Graham Foster; Sm Fazle Akbar; Salimur Rahman
Journal:  J Clin Exp Hepatol       Date:  2011-08-26

Review 3.  Evidence for association between hepatitis C virus and Parkinson's disease.

Authors:  Abdelrahman Ibrahim Abushouk; Mostafa Wanees Ahmed El-Husseny; Mayar Magdy; Ammar Ismail; Attia Attia; Hussien Ahmed; Ravikishore Pallanti; Ahmed Negida
Journal:  Neurol Sci       Date:  2017-08-05       Impact factor: 3.307

Review 4.  Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.

Authors:  Hussien Ahmed; Abdelrahman Ibrahim Abushouk; Amr Menshawy; Arwa Mohamed; Ahmed Negida; Samah A Loutfy; Mohamed M Abdel-Daim
Journal:  Clin Drug Investig       Date:  2017-11       Impact factor: 2.859

Review 5.  Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine.

Authors:  Yuewen Gong
Journal:  Chin J Integr Med       Date:  2012-03-30       Impact factor: 1.978

6.  Visualization of bile homeostasis using (1)H-NMR spectroscopy as a route for assessing liver cancer.

Authors:  G A Nagana Gowda; Narasimhamurthy Shanaiah; Amanda Cooper; Mary Maluccio; Daniel Raftery
Journal:  Lipids       Date:  2008-11-04       Impact factor: 1.880

7.  Association between hepatitis C and hepatocellular carcinoma.

Authors:  Luis Jesuino de Oliveria Andrade; Argemiro D'Oliveira; Rosangela Carvalho Melo; Emmanuel Conrado De Souza; Carolina Alves Costa Silva; Raymundo Paraná
Journal:  J Glob Infect Dis       Date:  2009-01

Review 8.  Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.

Authors:  Huimin Qin; Hongtao Li; Xiaolin Zhou; Fang Feng; Yanbing Shen; Hongku Tan; Feng Ye; Yingchun Xie
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

9.  Prevalence of hepatitis C infection in New York City, 2004.

Authors:  Katherine Bornschlegel; Magdalena Berger; Renu K Garg; Amado Punsalang; Christy M McKinney; R Charon Gwynn; Lorna E Thorpe
Journal:  J Urban Health       Date:  2009-11       Impact factor: 3.671

10.  Naturally occurring hepatitis C virus subgenomic deletion mutants replicate efficiently in Huh-7 cells and are trans-packaged in vitro to generate infectious defective particles.

Authors:  Laura Pacini; Rita Graziani; Linda Bartholomew; Raffaele De Francesco; Giacomo Paonessa
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.